Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PMD-026,Fulvestrant
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phoenix Doses First Patient in Dauntless-1 Phase 2 Trial of PMD-026 for RSK2-High BC
Details :
Product Name : PMD-026
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 20, 2025
Lead Product(s) : PMD-026,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable